✦ LIBER ✦

Ursodeoxycholic acid in cystic fibrosis-associated liver disease

✍ Scribed by Chee Y. Ooi; Scott Nightingale; Peter R. Durie; Steven D. Freedman

Book ID: 116619716
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 80 KB
Volume: 11
Category: Article
ISSN: 1569-1993
DOI: 10.1016/j.jcf.2011.08.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ursodeoxycholic acid therapy in cystic f

Ursodeoxycholic acid therapy in cystic fibrosis—associated liver disease: A dose-response study

✍ Carla Colombo; Andrea Crosignani; Marisa Assaisso; Pier Maria Battezzati; Mauro 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 668 KB

Previous studies from our groups have demonstrated improvements in biochemical markers of liver function when cystic fibrosis patients with associated liver disease were administered oral ursodeoxycholic acid. The magnitude of the response was somewhat less than that found when comparable doses (10

A two-year prospective study of the effe

A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis–associated liver disease

✍ Anders Lindblad; Hans Glaumann; Birgitta Strandvik 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 284 KB 👁 1 views

The efficacy of 2 years of treatment with ursodeoxycholic acid (UDCA) in cystic fibrosis (CF)-associated liver disease was evaluated by liver biopsies and liver function tests in 10 patients aged 8 to 28 years. The metabolism of UDCA was investigated by analysis of urinary bile acids with fast atom

Scintigraphic documentation of an improv

Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease

✍ Carla Colombo; Maria Rita Castellani; William F. Balistreri; Ettore Seregni; Mar 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 851 KB

We have previously documented that ursodeoxycholic acid exerts a beneficial effect on liver function and bile acid metabolism in patients with cystic fi- brosis. We hypothesized that the mechanism of action may be related in part to the choleretic properties of the administered bile acid. We therefo

Delayed intestinal visualization at hepa

Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease

✍ Carla Colombo; Andrea Crosignani; Pier Maria Battezzati; Maria Rita Castellani; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 790 KB

Effects of ursodeoxycholic acid therapy

Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis

✍ Carla Colombo; Kenneth D.R. Setchell; Mauro Podda; Andrea Crosignani; Aldo Roda; 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 685 KB

Ursodeoxycholic acid for liver disease a

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial

✍ C Colombo; P M Battezzati; M Podda; N Bettinardi; A Giunta 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 1 views

AND THE ITALIAN GROUP FOR THE STUDY OF URSODEOXYCHOLIC ACID IN CYSTIC FIBROSIS\* ment. Thus, we concluded that UDCA administration im-Liver disease is increasingly recognized as a major proves clinical and biochemical parameters in CF pacause of morbidity in cystic fibrosis (CF). Preliminary tients